Annual report pursuant to Section 13 and 15(d)

Revenue (Tables)

v3.22.0.1
Revenue (Tables)
12 Months Ended
Dec. 31, 2021
Revenue from Contract with Customer [Abstract]  
Schedule of Recognized Revenues
During the years ended December 31, 2021 and 2020, respectively, the Company recognized revenue from the following strategic partnerships and other license agreements (in thousands):
  Years Ended December 31,
  2021 2020
AstraZeneca $ 18,919  $ 8,308 
Seagen 768  9,702 
Servier 4,070  11,313 
Boston Pharmaceuticals 5,711  — 
Genentech 1,950  — 
Total Revenue $ 31,418  $ 29,323 
Schedule of Potential Milestone Payments
Under the Company´s existing strategic partnerships and other license agreements, the Company could receive the following potential milestone payments (in millions) as of December 31, 2021:
  Research, Development, Regulatory & Commercial Milestones Sales Milestones
AstraZeneca $ 1,096  $ 4,275 
Servier 136  102 
Seagen 754  450 
Boston Pharmaceuticals 88  265 
Genentech 844  600 
Total potential milestone payments $ 2,918  $ 5,692